In this study, high expression of CD73 in NSCLC patients receiving ICIs tended to be more prognostically favorable (CD73 TPS ≥50%) than low expression (TPS <50%), particularly in patients with EGFR mutation‐positive NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.